|
|
 |
|
Viewing report
|
|
|
|
China Asthma Drug Market Report 2009
Draco Healthcare Consulting LLC, May 2009, Pages: 103
According to the 2004 Global Burden of Asthma Report, there were about 300 million asthma patients worldwide. One out of every 250 disease-related deaths was caused by asthma. In China, the incidence rate of asthma patients has continuously increased in the recent years, especially among urban children. The latest survey shows that the incidence rate is 0.7% - 1.5% in adults and 0.11% - 2.03% in children.
Asthma has been known as a costly disease that is difficult to cure. On average asthma treatment will cost a patient over RMB 3000 per year in China. Assuming a national asthma population of 15 – 18 million and a 10% treatment rate, the cost of asthma treatment will be RMB 4.5 – 5.6 billion.
The Chinese asthma drug market reached RMB 1.7 billion in 1999. In 2007, asthma drug sales were RMB 4.855 billion (USD 714 million), an increase of 22.14% from 2006
This report has systemically analyzed the Chinese asthma drug market. All drug data are based on hospital drug prescription and drug purchasing data from the hospital data monitor system that the China Nan Fang Institute of Medical and Economic Information has developed and maintained (Nan Fang Institute is a direct subsidiary of the Chinese State Food and Drug Administration, the SFDA). Sampled hospitals are from major Chinese cities across different geographic locations, including Beijing, Shanghai, Guangzhou, Nanjing, Chengdu, Chongqing, Xian, Shenyang, Harbin and Zhengzhou, covering significant percentages of all hospitals in these regions.
Market shares from all major players including multinational and Chinese pharmaceutical companies and their major asthma products are analyzed systemically based on data from significant number of Chinese hospitals. The comprehensive hospital utilization data of major asthma drugs will present you a clear picture of the competition landscape of Chinese asthma drug market and the market potential for your company’s product(s) that already marketed in China or if you are planning to bring your drugs to the China market.
This China Asthma Drug Market Report has been a Must-have reference for all levels of decision makers in pharmaceutical companies, medical device companies, healthcare investing companies and healthcare consulting companies. These unique drug prescription and utilization data can provide valuable information for new product development, marketing and strategic planning functions for pharmaceutical companies. Compared to expensive customized drug reports in China, this multi-client report provides significant savings and great cost/benefit to pharmaceutical companies and interested parties.
Products Mentioned:
- Budesonide
- Salmeterol/ Floticasone
- Montelukast
- Doxofylline
- Compound Methoxyphenamine
- Ipratropium Bromide Aerosol
- Salbutamol
- Budesonide/ Formoterol
- Asarone
- Terbutaline
- Procaterol
- Floticasone Propionate
- Theosine
- Formoterol
- Tiotropium Bromide
- Beclometasone Dipropionate
- Tranilast
- Bambuterol
- Diprophylline
- Aminophylline
Customers who bought this item also bought
China Hypertension Drug Market 2009
Prescription Drugs - Global Strategic Business Report
China Senile Dementia Drug Market Report 2009
China Dermatosis Drug Market Report 2009
China Anti-Diabetic Drug Market Report 2009
Pharmaceuticals - Global Outlook
Anti-Hypertensive Drugs - Global Strategic Business Report
Cardiovascular Drugs - Global Strategic Business Report
Direct-To-Consumer (DTC) Advertising in Pharmaceuticals - Global Strategic Business Report
China Anti-Cancer Drug Market Report 2009
|
|
|
|
